In a study, NAD-229 antagonist for the 5-HT1A receptor and TCB-2 antagonists for the 5-HT2A receptor were able to prevent the progression of AD by reducing neuronal loss and oxidative stress in an AD model (Wistar rats) induced with streptozotocin [167] (Fig. 2D). Here, HTR1A is linked to Alzheimer disease.